AYTU BIOPHARMA, INC Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
AYTU BIOPHARMA, INC (AYTU) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$5.62 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-05-13
- AYTU BIOPHARMA, INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-03-31 was -$5.62M, a 434.60% decline year-over-year.
- AYTU BIOPHARMA, INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-12-31 was -$10.58M.
- AYTU BIOPHARMA, INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-09-30 was -$1.50M.
- AYTU BIOPHARMA, INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-03-31 was $1.68M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month |
|---|---|---|---|
| 2026-03-31 | -$5.62M 10-Q · filed 2026-05-13 | -$16.20M derived: sum of 2 quarters · filed 2026-05-13 | -$14.24M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$10.58M 10-Q · filed 2026-02-03 | -$8.62M 10-Q · filed 2026-02-03 | |
| 2025-09-30 | -$1.50M 10-Q · filed 2025-11-13 | ||
| 2025-03-31 | $1.68M 10-Q · filed 2026-05-13 | -$672.00K derived: sum of 2 quarters · filed 2026-05-13 | -$2.46M 10-Q · filed 2026-05-13 |
| 2024-12-31 | -$2.35M 10-Q · filed 2026-02-03 | -$4.14M 10-Q · filed 2026-02-03 | |
| 2024-09-30 | -$1.79M 10-Q · filed 2025-11-13 | ||
| 2024-03-31 | -$2.29M 10-Q · filed 2025-05-14 | -$9.14M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |